Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70207 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Tate Owen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Regulus Therapeutics, A Novartis Company, San Diego, CA, USA. Hauptthemen laut MEDLINE: MicroRNAs, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Regulus Therapeutics.
Abstract (Originalsprache)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease in adults and is characterized by progressive renal cyst formation and enlargement of the kidneys. The expression of microRNA‐17 (miR‐17) family is increased in kidney samples from ADPKD patients. RGLS4326 is a short oligonucleotide inhibitor of miR‐17 that preferentially distributes to the kidney and displaces miR‐17 from translationally active polysomes. Here, we present pharmacokinetics (PK), safety, and tolerability of RGLS4326 from phase 1 single‐ascending dose (SAD) and multiple‐ascending‐dose (MAD) studies in healthy subjects. Healthy adult subjects received a placebo or a single‐ascending subcutaneous dose of 0.05, 0.2, 0.6, 2, and 6 mg/kg or a multiple‐ascending dose of 0.1, 0.3, and 1 mg/kg (four doses, once every 2 weeks). In the SAD study, plasma exposures increased in a dose‐proportional manner across the dose range. Geometric mean t 1/2 values ranged from ≈3 to 8 h after subcutaneous injection to the abdomen, with longer t 1/2 values of ≈11 to 20 h and lower plasma exposures after subcutaneous injection to the upper arm or thigh. Urinary excretion increased with dose and ranged from 37% to 63%. In the MAD study, the mean elimination t 1/2 ranged from ≈5 to 7 h and plasma exposures increased in proportion to the dose range. The mean dose excreted in the urine for the 0.1 and 0.3 mg/kg doses was 35.2% to 39.3% compared to 46.5% to 48.1% for the 1.0 mg/kg dose. RGLS4326 was generally well tolerated, and no dose limiting treatment emergent adverse events were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regulus Therapeutics, A Novartis Company, San Diego, CA, USA.
ORCID-Profile: Tate Owen
Förderung
- Regulus Therapeutics
Zitieren
APA
Owen, T., Cole, I., Drygin, D., Valencia, T., Lee, E. C., Carlson, M., Ruff, L., Padgett, C., Cremer, K., Wright, T. M., Garg, R., Klassen, P., & Kamel, A. (2026). Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70207
Vancouver
Owen T, Cole I, Drygin D, Valencia T, Lee EC, Carlson M, et al. Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70207
BibTeX
@article{Owen2026,
author = {Owen, Tate and Cole, Izaiah and Drygin, Denis and Valencia, Tania and Lee, Edmund C and Carlson, Morgan and Ruff, Laura and Padgett, Claire and Cremer, Karl and Wright, Timothy M and Garg, Rekha and Klassen, Preston and Kamel, Amin},
title = {Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70207}
}
EUVIMED